10-K/A: RenovoRx Files 10-K/A to Remediate Internal Control Issues

RenovoRx, Inc. filed an amendment to its 2025 Annual Report to update risk factor disclosures and provide additional details regarding the remediation of previously identified material weaknesses in internal control over financial reporting.

Summary

• RenovoRx, Inc. filed Amendment No. 1 to its Form 10-K for the fiscal year ended December 31, 2025.
• The amendment is limited to revising Part I, Item 1A (Risk Factors) and Part II, Item 9A (Controls and Procedures).
• Management confirmed that previously identified material weaknesses in internal control over financial reporting were remediated as of December 31, 2025.
• The company reported net losses of approximately $11.2 million for the fiscal year ended December 31, 2025, compared to $8.8 million in 2024.
• Revenue from RenovoCath commercial sales reached approximately $1.1 million in 2025, up from $43,000 in 2024.
• As of March 23, 2026, the company held approximately $13.0 million in cash and cash equivalents.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral-to-cautious filing; while the remediation of internal control weaknesses is a positive governance development, the company remains in a precarious financial position with significant ongoing losses and Nasdaq listing risks.

Positives

• Successful remediation of previously identified material weaknesses in internal control over financial reporting as of December 31, 2025.
• Growth in commercial revenue from the RenovoCath device, reaching $1.1 million in 2025.
• Management maintains that internal control over financial reporting was effective as of year-end 2025.

Negatives

• Continued significant net losses, totaling $11.2 million for 2025.
• Accumulated deficit of approximately $61.4 million as of December 31, 2025.
• Non-compliance with the Nasdaq minimum bid price requirement of $1.00 per share as of December 31, 2025.
• Reliance on a single supplier for the RenovoCath delivery system.

Risks

• Potential delisting from the Nasdaq Capital Market if minimum bid price requirements are not met.
• Uncertainty regarding the ability to continue as a going concern if additional capital is not raised.
• High degree of risk associated with the clinical-stage development of the IAG drug/device combination.
• Dependence on the success of the Phase III TIGeR-PaC study, with final data readout not expected until 2027.
• Risks related to the commercialization of the RenovoCath device as a standalone product.
• Potential for future material weaknesses in internal controls if remediation efforts prove insufficient.

Future Outlook

The company expects to continue incurring net losses until FDA approval for its product candidate is received or RenovoCath commercial sales generate sufficient revenue. Final data from the Phase III TIGeR-PaC study is anticipated in 2027.

Management Comments

• Management concluded that previously identified material weaknesses were remediated as of December 31, 2025.
• Management believes current cash and cash equivalents are sufficient to fund operations for at least the next twelve months.

Industry Context

StockSavvy.ai notes that RenovoRx is navigating the difficult transition from a clinical-stage research entity to a commercial-stage medical device company. The remediation of internal controls is a critical step for maintaining Nasdaq listing status and investor confidence, common challenges for small-cap biotech firms.

Comparison to Industry Standards

• The company's reliance on a single-source manufacturer for its primary device is a common but significant risk factor for early-stage medical device companies.
• The use of Orphan Drug Designation is a standard strategic approach for oncology-focused biotechs to secure market exclusivity.
• The company's financial profile, characterized by recurring losses and reliance on equity financing, is typical for clinical-stage biopharmaceutical companies.

Management Changes

Corporate Governance

Legal Proceedings

• None disclosed in this filing.

Related Party Transactions

• None disclosed in this filing.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises.
• Investors are alerted to the risk of Nasdaq delisting.
• The company's ability to continue as a going concern remains a focus for creditors and investors.

Next Steps

• Regain compliance with Nasdaq minimum bid price requirements.
• Continue commercialization efforts for the RenovoCath device.
• Advance the Phase III TIGeR-PaC clinical study toward a 2027 data readout.
• Monitor cash burn and evaluate potential future capital raising activities.

Key Dates

Recommendation

The company is in a high-risk, clinical-stage phase with significant cash burn and Nasdaq listing issues. While the remediation of internal controls is positive, the stock remains speculative until clinical trial results are finalized and commercial revenue scales significantly.

Keywords

RenovoRx, RNXT, RenovoCath, biopharmaceutical, oncology, internal controls, SEC filing, 10-K/A, Nasdaq compliance